Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Proteasome inhibition alleviates prolonged moderate compression-induced muscle pathology

BMC Musculoskeletal Disorders201112:58

https://doi.org/10.1186/1471-2474-12-58

©  Siu et al; licensee BioMed Central Ltd. 2011

  • Received: 30 April 2010
  • Accepted: 7 March 2011
  • Published:
Open Peer Review reports

Abstract

Background

The molecular mechanism initiating deep pressure ulcer remains to be elucidated. The present study tested the hypothesis that the ubiquitin proteasome system is involved in the signalling mechanism in pressure-induced deep tissue injury.

Methods

Adult Sprague Dawley rats were subjected to an experimental compression model to induce deep tissue injury. The tibialis region of the right hind limb was subjected to 100 mmHg of static pressure for six hours on each of two consecutive days. The compression pressure was continuously monitored by a three-axial force transducer within the compression indentor. The left hind limb served as the intra-animal control. Muscle tissues underneath the compressed region were collected and used for analyses.

Results

Our results demonstrated that the activity of 20S proteasome and the protein abundance of ubiquitin and MAFbx/atrogin-1 were elevated in conjunction with pathohistological changes in the compressed muscle, as compared to control muscle. The administration of the proteasome inhibitor MG132 was found to be effective in ameliorating the development of pathological histology in compressed muscle. Furthermore, 20S proteasome activity and protein content of ubiquitin and MAFbx/atrogin-1 showed no apparent increase in the MG132-treated muscle following compression.

Conclusion

Our data suggest that the ubiquitin proteasome system may play a role in the pathogenesis of pressure-induced deep tissue injury.

Keywords

  • Pressure Ulcer
  • Ubiquitin Proteasome System
  • Duchenne Muscular Dystrophy
  • Proteasome Inhibitor MG132
  • MG132 Treatment

Background

Pressure ulcer represents a considerable clinical problem. An estimated one billion dollars is spent annually to manage pressure ulcers in the United States [1]. A pressure ulcer is defined as localized damage to the skin and the underlying tissues in response to moderate but sustained mechanical compression [2]. The exact cause and pathogenesis of pressure ulcers are largely unknown. Pressure ulcers are generally categorized into superficial or deep pressure ulcers. These are distinctly differentiated based on their developmental processes. A superficial ulcer is confined to the skin layer, and can be diagnosed visually at an early stage. In contrast, a deep ulcer originates in the underlying tissues overlying a bony prominence in the compressed region, and its development involves subsequent progression of the injury upwards until it penetrates to the skin [3]. Deep ulcer is of considerable clinical concern as the tissue damage is already very severe by the time the ulceration becomes visible and detectable at the cutaneous layer. This makes the prognosis very uncertain and hinders therapeutic follow-up. To better characterize this serious form of pressure ulcer, the term "deep tissue injury" has been introduced by the US National Pressure Ulcer Advisory Panel (NPUAP) in order to emphasize that deep pressure ulcer occurs as "a pressure-related injury to subcutaneous tissues under intact skin" [4–9].

Ubiquitin proteasome system is a non-lysosomal cellular process responsible for the housekeeping functions of the regulation of protein turnover and the elimination of abnormal proteins in eukaryotic cells. This system has been shown to be involved in the regulation of important biological events including cell division, stress response [10], signalling transduction [11, 12], transcription, and protein sorting [13]. Ubiquitin proteasome system could probably be one of the potential candidates of the molecular target responsible for the pathogenesis of pressure ulcer. In particular, the ubiquitin proteasome system signalling has been shown to be critical for coordinating muscle degradation [14]. In this pathway, proteins tagged with a polyubiquitin signal are degraded by a proteasome complex. Ubiquitination is the process of the covalent attachment of ubiquitin to a protein substrate. The formation of a polyubiquitin chain essentially relies on the E3 ligases which function to selectively recognize their specific protein substrates [15]. Muscle specific E3 ubiquitin ligases, including muscle atrophy F-box/atrophy gene-1 (MAFbx/atrogin-1) and muscle ring finger 1 (MuRF1), have been previously identified [16, 17]. MAFbx/atrogin-1 contains an F-box domain which is a characteristic motif found in the SCF (Skp1, cdc53/cullin and F-box protein) subfamily of E3 ubiquitin ligases. The F-box functions to link the elements of the E3 complex to the targeted protein [15, 18]. MuRF1 belongs to the RING Finger E3 ligase subfamily which was initially found in association with the myofibril [18, 19]. These two muscle-specific E3 ligases have been demonstrated to be upregulated in muscle degradation due to disuse and to catabolic conditions. They are generally considered as the critical regulatory components of the ubiquitin-proteasome system mediated catabolic process [2, 14, 15, 20].

Research has resulted in some but limited understanding of the etiology of pressure ulcer. The identified critical risk factors include shear, moisture, friction, malnutrition, and pressure [21, 22]. Yet, the fundamental knowledge of the pathology of deep pressure ulcer is still missing. The cellular signalling events coordinating deep tissue injury need to be revealed so that novel preventive and treatment regimens can be developed. Driven by the fact that skeletal muscle tissue is particularly sensitive to prolonged compression [23–26] and the destructive nature of the ubiquitin proteasome system in muscle [18, 27, 28], the present study investigated whether the muscle ubiquitin proteasome system is involved in the underlying mechanism of the pathology of deep pressure ulcer. We tested the hypothesis that the muscle ubiquitin proteasome system plays a causative role in pressure-induced deep tissue injury. As the pathogenesis of deep pressure ulcer might involve the hypoxia- and cellular deformation-related mechanisms, the gene expression levels of molecular markers of hypoxia and cellular chaperone including hypoxia inducible factor (HIF-1α) and heat shock protein70 (HSP70) were also investigated in this study.

Methods

Animals

Female adult Sprague Dawley rats weighing about 300 g were used in this study. The animals were kept in conventional housing under pathogen-free conditions, exposed to a reverse light condition of 12:12-hours light-dark, and fed with standard nutrient diet and water ad libitum. Animal research ethics approval was obtained from the Animal Ethics Sub-committee of The Hong Kong Polytechnic University. The animal care standards were followed by adhering to the recommendations for the care of laboratory animals as advocated by the American Association for Accreditation of Laboratory Animal Care (AAALAC) and following the policies and procedures detailed in the Guide for the Care and Use of Laboratory Animals as published by the U.S. Dept. of Health and Human Services and proclaimed in the Animals Welfare Act.

Muscle Compression Procedure

After acclimatization with the housing environment, rats (N = 8) were subjected to an in vivo pressure-induced deep tissue injury protocol, previously established in the same laboratory, with minor modifications [29–31]. Briefly, animals were first anesthetized with ketamine (80 mg/kg) and xylazine (8 mg/kg) by intra-peritoneal (i.p.) injection. One third of the initial dose was i.p. administered approximately one to two times throughout the compression procedure to maintain the level of anaesthesia. Anesthetization was assured by testing the loss of reflex action and moustache dithering test. The hind limbs were shaved with an electronic razor before being subjected to compression, which involved moderate prolonged compression loading with a static pressure of 100 mmHg. This was applied to an area of 1.5 cm2 over the tibialis region of the right limb. The loading duration was six hours on each of two consecutive days. The compression force was continuously monitored by a three-axial force transducer within the compression indentor. A laser Doppler flowmetry (DRT4, Moor Instruments, Axminster, UK) with a contact probe (DP1T/7-V2) was used to monitor the blood flow of the compression site as previously described [29]. The left uncompressed limb served as intra-animal control. Rats were killed by overdose of ketamine and xylazine twenty hours after the last session of compression. Tissue samples were excised from the area directly underneath the indentor region, frozen in liquid nitrogen-cooled isopentane and stored at -80°C until further analysis. To examine the MAFbx/atrogin-1 protein expression in muscle immediately after the compression protocol, muscle samples of the rats that were sacrificed immediately after two sessions of 6-hours of compression over two consecutive days (2D-IM group) [31] were used to perform Western blot analysis of MAFbx/atrogin-1.

Administration of Proteasome Inhibitor

Rats were randomly divided into two groups to receive either MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO) or DMSO (vehicle control) administration (N = 5 per group). MG132, a cell-permeable peptide aldehyde that inhibits the major peptidase activities of proteasome [32] was purchased from Merck and dissolved in DMSO for use. A dose of 10 mg/kg of MG132 that has been used in previous studies was adopted in this study [33, 34]. The MG132 administration was carried out by two intraperitoneal injections of 5 mg/kg of MG132 right before each of the two 6-hours compression sessions. Equal volumes of DMSO were administered to the control animals.

Histological Analysis

Standard hematoxylin and eosin staining procedure was used to examine the histology of tissues. Ten micro-meters thick cross-sections were prepared from frozen muscle tissue samples in a cryostat at -20°C. The sections were air dried at room temperature and fixed with 10% formalin solution (HT-5011, Sigma Aldrich). Samples were stained with Mayer's hematoxylin (MHS-1, Sigma Aldrich) and 1% eosin in CaCl2 (318906, Sigma Aldrich) following a series of alcohol-mediated dehydration steps, and stained sections were mounted in clarion mounting medium (C-0487, Sigma Aldrich).

Real time Quantitative PCR Analysis

Total RNA was extracted from frozen compressed and control muscle samples with TriReagent (Molecular Research Center) based on the guanidine thiocynate method. Muscle samples were homogenized mechanically in ice-cold TriReagent. The extracted total RNA was solubilized in RNase-free H2O and quantified by spectrophotometry at λ = 260 nm and the purity of RNA was confirmed by examining the 260/280 ratio. Superscript III reverse transcriptase kit (Invitrogen Life Technology) was used to generate complementary DNA (cDNA). Reverse transcription was performed by following the manufacturer's recommendations, with a reaction volume of 20 μl which included 1 μg of total RNA, decamer primers and superscript reverse transcriptase. For the cDNA prepared from the preliminary samples collected from the rats which had not been treated with DMSO or MG132, the PCR reaction was performed in TaqMan Master Mix, primer and Taqman probes, and RNase and DNase free water on an ABI7500 real time PCR thermocycler (Applied Biosystems). Primers and probes for the TaqMan assay were designed specifically against the sequence of rat MAFbx/atrogin-1, MuRF1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by the manufacturer [MAFbx/atrogin-1: NM_133521.1 (GenBank accession number), Rn00591730_m1 (Applied Biosystems TaqMan assay ID), 61 bp (Amplicon length); MuRF-1: NM_080903.1, Rn00590197_m1, 56 bp; GAPDH: NM_017008.3, Rn99999916_s1, 87 bp]. For the TaqMan PCR, GAPDH was used as internal control and the relative quantification of gene expression was calculated using the comparative threshold cycle ΔΔCT method [35]. For the cDNA prepared from the samples collected from the rats which had been treated with DMSO or MG132, the PCR reaction was performed in SYBR green/ROX qPCR Master Mix (Fermentas) with forward and reverse primers for ubiquitin, MAFbx/atrogin-1, HIF-1α, HSP70 or β2 microglobulin (β2M) (Table 1), and RNase/DNase-free water in ABI7500 real time PCR thermocycler (Applied Biosystems). For the SYBR green/ROX-mediated PCR, β2M was included as internal housekeeping control gene. A relative standard curve (concentration vs. threshold cycle) of target and reference genes for quantification of PCR products was generated by dilution of cDNA from the calibrator. Complementary DNA prepared from uncompressed control samples was used as the calibrator to generate the standard curve. Results were expressed as the concentration ratio of the target gene to β2M of each sample. All PCR amplification and sequences were verified and the threshold for kinetic detection was set to occur over linear amplifications over several ranges of primers and RNA levels. The amplification efficiency for the PCR reactions was assessed by including serially diluted cDNAs with known DNA concentrations as positive control. All samples were run in duplicate, with control and compressed samples run on the same plate.
Table 1

Primer Used in Real Time RT-PCR Analysis

Gene

Accession Number

Primers

  

(F; forward primer, R; reverse primer)

Ubiquitin

NM017314

F: 5'GGGCATGCAGATCTTTGTGAA3'

  

R: 5'ACCTCCAGGGTGATGGTCTTG3'

MAFbx/atrogin-1

NM133521

F: 5'TGAAGACCGGCTACTGTGGAAGAGAC3'

  

R: 5'TTGGGGTGAAAGTGAGACGGAGCAG3'

HIF-1α

NM024359

F: 5'AACAAACAGAATCTGTCCTCAAACC3'

  

R: 5'CAGGTAATGGAGACATTGCCAG3'

HSP70-1

X77207

F: 5'CGAGGGCATCGACTTCTACACG3'

  

R: 5'ATCTGCGCCTTGTCCAGCTTG3'

HSP70-2

X77208

F: 5'CTCGTCCATGGTGCTGACCAAG3'

  

R: 5'CCGCTGCGAGTCGTTGAAGTAG3'

HSP70-3

X77209

F: 5'AGGACTCAACGTGCTGCGAATC3'

  

R: 5'TCAGGATGGACACGTCGAACG3'

β2M

NM012512

F: 5'CGTGATCTTTCTGGTGCTTGTC3'

  

R: 5'TTCTGAATGGCAAGCACGAC3'

Proteasome Activity Assay

The proteasome enzymatic activity was measured by using a proteasome 20S assay kit (Enzo Life Sciences) following the manufacturer's instructions. In brief, the protein extract from muscle tissue was used to perform assessment of proteasome 20S activity by measuring the hydrolysis of a fluorogenic peptidyl substrate Suc-Leu-Leu-Val-Tyr-AMC (AMC: 7-amino-4-methylcoumarin) following the 0.03% sodium dodecyl sulphate-activation step. This substrate was cleaved by the proteasome activity and the subsequently released free AMC was then detected by a fluorimeter with an excitation wavelength of 380 nm and emission wavelength of 460 nm. The fluorescence signal was monitored before and after one-hour incubation at 37°C. The change in fluorescence signal was normalized to the amount of protein used in the assay.

Immunocytochemical Analysis

Frozen tissue cross-sections were cut to a thickness of 10 μm in a cryostat at -20°C. The sections were air dried at room temperature and fixed with 10% formalin solution (Sigma Aldrich). Background activity was minimized by blocking the section with 5% goat serum. After washing, sections were incubated with anti-ubiquitin mouse monoclonal (3936, Cell Signaling), anti-MAFbx rabbit polyclonal (sc-33782, Santa Cruz Biotechnology) or anti-MuRF1 rabbit polyclonal (sc-32920, Santa Cruz Biotechnology) antibodies. Sections were then processed by using Vectastain Elite ABC Peroxidase kit (PK6100, Vector Laboratories) with ImmPACT DAB peroxidase substrate (SK4105, Vector Laboratories) or exposed to anti-rabbit IgG (H+L) fluorescein-conjugated secondary antibody (FI-1000, Vector Laboratories). Negative controls were performed by eliminating the primary or secondary antibody. Sections were examined under a Nikon 80i microscope. Images were captured with a Nikon DXM 1200C camera using Nikon ACT-1C software.

Western Blot Analysis

Protein abundance of ubiquitin and MAFbx/atrogin-1 was measured in the compressed and control muscles. Soluble protein was extracted from muscle samples by the following procedure. After mincing and homogenization in ice-cold lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, pH 7.4, 20% glycerol, 0.1% Triton X-100, and 1 mM dithiothreitol), muscle homogenate underwent serial centrifugations. Protease inhibitor cocktail (P8340, Sigma-Aldrich) was added to the extracted protein followed by spectrophotometric measurement of protein concentration at 595 nm using a commercial Bradford method (Coomassie Protein Assay, Pierce). The protein concentration was determined in duplicate by following the manufacturer's recommendations with bovine serum albumin (BSA) used as standard. Protein extracts were then boiled at 95°C for 5 min in Laemmli buffer with 5% β-mercaptoethanol. Forty μg of protein was loaded on a 10% polyacrylamide gel. After electrophoretic separation by SDS-PAGE, the proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon P, Millipore). The membranes were blocked in 5% nonfat milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h at room temperature after the transfer, and incubated overnight at 4°C with corresponding primary antibody: anti-ubiquitin mouse monoclonal antibody (1:1000 dilution, 3936, Cell Signaling) or anti-MAFbx/atrogin-1 rabbit polyclonal antibody (1:200 dilution, sc33782, Santa Cruz) diluted in TBST with 2% bovine serum albumin (BSA). Membranes were then washed in TBST and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 h (1:3000 dilution, 7076 for anti-mouse antibody, 7074 for anti-rabbit antibody, Cell Signaling). Luminol reagent (NEL103001EA, Perkin Elmer) for chemiluminescent detection of HRP was then applied. The chemiluminescent signal was captured with a Kodak 4000R Pro camera. The resulting bands were quantified as optical density (OD) x band area and expressed as arbitrary units. β-tubulin (1:2000 dilution, T0198, Sigma Aldrich) was probed and used as the reference of internal control. Data on ubiquitin and MAFbx/atrogin-1 were expressed by normalizing to the signal of β-tubulin.

TUNEL Analysis

DNA strand breaks were assessed by fluorescent labelling of terminal dUTP nick end labelling (TUNEL) using a detection kit according to the manufacturer's instructions (11684795910, Roche Applied Science). In brief, 10 μm thick frozen sections were cut in a freezing cryostat at -20°C. Tissue sections were air dried at room temperature, fixed with 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton X-100 in 0.1% sodium citrate, and incubated with the fluorescein-conjugated TUNEL reaction mixture. A section treated with DNase I was examined as positive control. Omission of the addition TdT enzyme in the TUNEL reaction mixture was included as negative control. The sections were then mounted with DAPI mounting medium to visualize nuclei (Vectashield mounting medium, Vector Laboratories). TUNEL- and DAPI-stained nuclei were examined under a fluorescence microscope (Biological Research Microscope 80i, Nikon) equipped with a digital camera (DXM 1200c, Nikon) using Nikon ACT-1C software. SPOT RT software (Diagnostic Instruments) was then used to stack and analyse the images.

Statistical Analysis

All data are presented as mean ± standard error of mean. One-way ANOVA with Tukey HSD post hoc test was used to examine differences between groups. Level of statistical significance was set at p < 0.05.

Results

Compression induced muscle pathohistology and increase in MAFbx/atrogin-1 protein expression

Preliminary experiments were conducted in rats which had not been treated with DMSO or MG132 to demonstrate the potential involvement of the ubiquitin proteasome system in compression-induced muscle pathology. Gross muscle histology and expression of ubiquitin E3 ligases, MAFbx/atrogin-1 and MuRF1 were examined. Histological analysis demonstrated the presence of pathological muscle changes following compression (Figure 1 A and 1B). These included loss of angular shape and rounding contour of cross-sectional muscle fibres, increase in nuclei number in the interstitial space, increased proportion of interstitial space, and internalization of peripherally located nuclei in muscle cells (Figure 1 B). These pathohistological characteristics were noticeably in contrast to the normal histology of muscle cells in uncompressed samples which showed tightly packed muscle fibres with polygonal shape and peripherally located nuclei (Figure 1 A). According to our fluorescent immunocytochemical analysis, immunoreactivity of MuRF1 was found to be unchanged in muscle in response to compression. However, immunoreactivity of MAFbx/atrogin-1 localized in the cytoplasmic region of the compressed muscle was apparently increased when compared to uncompressed muscle (Figure 1 C and 1D). The mRNA expression of MAFbx/atrogin-1 and MuRF1 was also examined by real time quantitative PCR. No significant difference in mRNA content of MAFbx/atrogin-1 and MuRF1 was observed with compression treatment.
Figure 1
Figure 1

Compression-induced Pathohistology and Increase in MAFbx/atrogin-1. Preliminary experiments were conducted to expose untreated rats (neither DMSO nor MG132) to the compression protocol to examine the effect of compression on gross muscle histology and expression of ubiquitin E3 ligases, MAFbx/atrogin-1 and MuRF1. Gross muscle histology was examined following hematoxylin and eosin staining. Muscle tissue after compression generally showed pathohistological appearances including rounding shaped muscle cells, accumulated nuclei number, and internalization of peripherally located nuclei in muscle cells (as shown by arrows in B). Fluorescent immunocytochemical analysis demonstrated that the protein expression of MAFbx/atrogin-1 was apparently elevated in cytoplasmic region of the compressed muscle (D) relative to uncompressed muscle (C). No noticeable change in immunoreactivity of MuRF1 was found in the compressed and uncompressed muscles (data not shown).

MG132 treatment alleviated compression-induced muscle pathohistology

The gross muscle histological changes as induced by compression in DMSO vehicle-treated rats were similar to that in the untreated rats. Histological analysis demonstrated that changes such as loss of tightly packed polygonal arrangement of muscle cells, round shaped contour of muscle cells, and increase in nuclei number were generally observed in compressed muscle of DMSO-treated animals (Figure 2 upper panels). In contrast, these pathohistological appearances were not seen in the muscle of MG132-treated animals following compression (Figure 2 lower panels).
Figure 2
Figure 2

Histological Analysis. Muscle histology was examined following hematoxylin and eosin staining. Histologic appearances indicating muscle pathology such as loss of tightly packed polygonal muscle cells arrangement, round shaped contour of muscle cells, and increment of nuclei number were generally observed in compressed muscle of DMSO-treated animals but not MG132-treated animals.

MG132 treatment precluded compression-induced elevation of 20S proteasome activity

The 20S proteasome activity in compressed muscle of DMSO-treated animals was significantly increased by 105% relative to the uncompressed muscle (Figure 3). In MG132-treated animals, no significant difference was found in 20S proteasome activity between compressed and uncompressed muscles (Figure 3).
Figure 3
Figure 3

20S Proteasome Activity Assay. 20S proteasome activity was increased in the compressed muscle of DMSO-treated animals but not MG132-treated animals. Results were expressed as change in fluorescence unit normalized to the amount (milligrams) protein used in the assay. Data are presented as means ± SEM. *p < 0.05 compared with the uncompressed muscle of DMSO-treated animals.

MG132 treatment precluded compression-induced increase in ubiquitin and MAFbx/atrogin-1

The protein content of ubiquitin and MAFbx/atrogin-1 was examined by immunocytochemical analysis. Marked immunopositive staining of ubiquitin was found to be localized in the cytoplasmic region of scattered muscle fibres with round contours in the compressed muscle of DMSO-treated rats whereas no immunoreactivity of ubiquitin was detected in uncompressed muscle of DMSO-rats (Figure 4 upper panels). In contrast, immunoreactivity of ubiquitin was not detected in either uncompressed or compressed muscles of MG132-treated rats (Figure 4 lower panels). According to our immunocytochemical analysis, MAFbx/atrogin-1 protein abundance was apparently increased in the compressed muscle relative to uncompressed muscle of DMSO-rats (Figure 5 upper panels). However, MAFbx/atrogin-1 protein content was not changed in compressed muscle when compared to uncompressed muscle in MG132-treated rats (Figure 5 lower panels). MuRF1 protein abundance was also examined but no apparent change was found in the compressed muscle relative to uncompressed muscle in both DMSO- and MG132-treated animals (data not shown). According to our Western immunoblot analysis, the protein abundance of ubiquitin was significantly increased by 4.8-folds in the compressed muscle when compared to uncompressed muscle of DMSO-treated rats. The protein abundance of ubiquitin appeared to be increased in the compressed muscle relative to the uncompressed muscle in MG132-treated rats but this did not reach the statistical significance level (p > 0.05) (Figure 6). The protein abundance of MAFbx/atrogin-1 was significantly increased by 5.2-folds in the compressed muscle when compared to uncompressed muscle of DMSO-treated animals whereas no significant difference was found between compressed and uncompressed muscles in MG132-treated animals (Figure 6).
Figure 4
Figure 4

Immunocytochemical Analysis of Ubiquitin. DAB-mediated immunostaining was used to examine the ubiquitin protein abundance in uncompressed and compressed muscles of DMSO- and MG132-treated animals. In DMSO-treated rats, uncompressed muscle did not show any immunoreactivity of ubiquitin whereas compressed muscle demonstrated strong immunoreactivity in the muscle cells (upper panels). The ubiquitin immunoreactivity was distributed in muscle fibres in a scattered pattern. In MG132-treated rats, no immunoreactivity of ubiquitin was detected in both uncompressed and compressed muscles (lower panels).

Figure 5
Figure 5

Immunocytochemical Analysis of MAFbx/atrogin-1. DAB-mediated immunocytochemistry was used to examine the protein abundance of MAFbx/atrogin-1 in uncompressed and compressed muscles of DMSO- and MG132-treated animals. Uncompressed muscle of both DMSO- and MG132-treated rats did not show any immunoreactivity of MAFbx/atrogin-1. Apparent positive immunoreactivity was detected in the muscle fibres of compressed muscle in only DMSO-treated rats but not in MG132-treated rats.

Figure 6
Figure 6

Protein Expression of Ubiquitin and MAFbx/atrogin-1. Panel A shows the representative Western immunblots of ubiquitin, MAFbx/atrogin-1, and β-tubulin in compressed and control muscles in two pairs of DMSO and MG132 treated animals. The protein expression of ubiquitin and MAFbx/atrogin-1 was determined by Western blot. Data are presented as net intensity x resulting band area and expressed in arbitrary units. Results of ubiquitin (B) and MAFbx/atrogin-1 (C) were normalized to corresponding β-tubulin signal.

MG132 treatment precluded compression-induced decrease in HSP70-3 mRNA expression

According to our real time PCR analysis, the mRNA content of ubiquitin and MAFbx/atrogin-1 appeared to be decreased in the compressed muscle relative to uncompressed muscle in DMSO- and MG132-treated animals but these changes did not reach the statistical significance level (p > 0.05) (Figure 7). No significant difference was found in the mRNA abundance of HIF-1α, HSP70-1, and HSP70-2 between the compressed and uncompressed muscles in DMSO- and MG132-treated rats (Figure 7). The mRNA abundance of HSP70-3 was significantly decreased by 69% in the compressed muscle when compared to uncompressed muscle of DMSO-treated rats whereas no significant difference was found between the compressed and uncompressed muscles in MG132-treated animals (Figure 7).
Figure 7
Figure 7

mRNA Expression of Ubiquitin, MAFbx/atrogin-1, HIF-1α, HSP70-1, HSP70-2, and HSP70-3. The mRNA expression levels of Ubiquitin (A), MAFbx/atrogin-1 (B), HIF-1α (C), HSP70-1 (D), HSP70-2 (E), and HSP70-3 (F) in compressed and control muscles in DMSO and MG132 treated animals were evaluated by real time PCR analysis. Data are expressed as expression ratio normalized to β2M gene and presented as mean ± SEM with significance level set at *p < 0.05, compressed muscle compared to control uncompressed muscle in the corresponding group.

MG132 treatment precluded compression-induced increase in DNA strand breaks

TUNEL-positive nuclei were not detected in the uncompressed muscle of DMSO-treated animals whereas TUNEL-positive nuclei were observed in the compressed muscle of DMSO-treated animals. There were no TUNEL-positive nuclei detected in either the uncompressed or the compressed muscle of MG132-treated animals (Figure 8).
Figure 8
Figure 8

TUNEL Analysis. DNA strand breaks in uncompressed and compressed muscles of DMSO-treated and MG132-treated animals were assessed by TUNEL assay. TUNEL labelling was stained in green and nuclei were labelled by DAPI staining in blue. TUNEL-positive nuclei were identified in the images as shown by arrows.

MAFbx/atrogin-1 protein expression was increased immediately after compression

According to our Western blot analysis, the protein abundance of MAFbx/atrogin-1 was significantly increased by 96% in the compressed muscle of 2D-IM group (i.e., rats were sacrificed immediately after two sessions of 6-hours of compression over two consecutive days) (Figure 9).
Figure 9
Figure 9

Protein Expression of MAFbx/atrogin-1 Immediately After Compression. The protein expression of MAFbx/atrogin-1 in muscle tissues collected immediately after the compression procedure was determined by Western blot. Data are presented as net intensity x resulting band area and expressed in arbitrary units. Result of MAFbx/atrogin-1 was normalized to corresponding β-tubulin signal. Data are presented as mean ± SEM. *p < 0.05, compressed muscle compared to uncompressed control muscle.

Discussion

Pressure-induced deep tissue injury is a severe, life-threatening form of pressure ulcer which causes considerable health concern because there are no effective treatments. There is an urgent need to understand the pathology of deep ulcer in order to identify the molecular targets for exploring new therapeutic regimens. In this study, our novel data demonstrated that the ubiquitin proteasome system is activated as indicated by the elevation of proteasome activity, ubiquitin, and the muscle-specific ubiquitin E3 ligase MAFbx/atrogin-1 in an experimental deep tissue injury protocol. Our data further demonstrated that proteasome inhibitor MG132 prevented the compression-induced increases in ubiquitin, MAFbx/atrogin-1, and 20S proteasome activity, and alleviated the muscle pathohistology induced by prolonged moderate compression. These results strongly suggested that the muscle ubiquitin proteasome system plays a role in the underlying mechanisms of deep pressure ulcer.

The ubiquitin proteasome system has been shown to function in the breakdown of muscle [36]. Ubiquitin E3 ligases are essential components in the ubiquitin proteasome system, and have been demonstrated to be expressed in increased amounts in catabolic conditions, during muscle atrophy, metabolic dysregulation, burn injury, inflammation, eccentric exercise-induced muscle damage, alcohol intoxication, and spinal cord injury [37–43]. The ubiquitin proteasome system signalling has not been investigated in pressure-induced muscle injury previously. Our immunocytochemical and biochemical data presented here illustrate that ubiquitin and MAFbx/atrogin-1 protein expression and 20S proteasome activity were elevated in response to sustained moderate compression. It is worth noting that the expression pattern of MAFbx/atrogin-1 was localized concurrently with the inflammation-associated pathohistological appearance such as the massive accumulation of nuclei in the interstitial space of muscle tissue. These observations were generally consistent with previous findings showing that MAFbx/atrogin-1 and MuRF1 were induced in response to acute inflammation as initiated by lipopolysaccharide injection and sepsis [44]. This strengthens the case that the increase in the expression of MAFbx/atrogin-1 and ubiquitin is linked to the proposed role of the ubiquitin proteasome system in the pathogenesis of deep tissue injury.

Pharmacological inhibition of the ubiquitin proteasome system using MG132 has been meticulously investigated in skeletal muscle disorders such as muscle dystrophy. Bonuccelli and colleagues have examined the effect of MG132 treatment on the mdx phenotype-related reduction of the dystrophin and dystrophin-associated proteins expression in skeletal muscle fibres from mdx mice [45]. By using the technique of immunofluorescence and Western immunoblotting, the administration of MG132, either by local injection into the muscle or osmotic minipump-mediated systemic treatment, was demonstrated to effectively rescue the expression level and sarcolemmal localization of dystrophin, β-dystroglycan, α-dystroglycan, and α-sarcoglycan in gastrocnemius muscle of mdx mice [45]. The histological analysis also illustrated the decrease in the extent of pathological changes in the muscle of mdx mice following 8-days of systemic treatment with MG132 [45]. By using a tissue explant culture model in examining the isolated skeletal muscle biopsies, MG132 treatment was further demonstrated to be successful in restoring the expression of the protein component of dystrophin-glycoprotein complex comprising dystrophin, β-dystroglycan, and α-sarcoglycan at the sarcolemma of muscles from patients with Duchenne muscular dystrophy (DMD) and Becker muscle dystrophy (BMD) [46]. Although the nature of myopathy in pressure-induced deep tissue injury is different from the dystrophin-deficiency disorders (i.e., patients with DMD/BMD and mdx mice), the present findings indicated that the inflammation-associated myopathic histology as induced by sustained compression can also be alleviated by MG132 treatment. These results were consistent with the reported protective effect of MG132 in muscle of mdx mice and DMD/BMD patients [45, 46]. A notable finding refers to the alleviation of the immune cells infiltration in the compressed muscle of the MG132-treated animals. The mechanism responsible for this phenomenon is not known. It is speculated that the relationship between the ubiquitin proteasome system and immune cell signalling (e.g., NF-kappaB activation) might account for the presently observed phenomenon [11, 12]. In support to the present findings, proteasome inhibitors have been demonstrated to have anti-inflammatory activities by blocking the activation of NF-kappaB and by reducing the production of inflammatory mediators and cytokines [47, 48]. Furthermore, the in vivo administration of peptide aldehyde inhibitor MG132 has been shown to reduce diabetes after adoptive transfer of autoreactive T cells to nonobese diabetic mice lacking endogenous T cells and this was probably associated with the prevention of T cell proliferation [49]. Their data also illustrated that MG132 can prevent the proliferation of BDC2.5 T cells in vitro in a dose-dependent fashion [49]. Intriguingly, the effects of proteasome inhibitors on blocking the cell cycle entry of T cells and reducing the severity of some immune-mediated disorders have been demonstrated [47, 50, 51]. Collectively, though the exact mechanism in explaining the rescuing effect of proteasome inhibitor in deep pressure ulcer is not known, the present findings might have clinical implications in the management of deep pressure ulcer.

An intriguing finding in this study is the prevention of increased DNA strand breaks as measured by TUNEL in the MG132-treated muscle following compression. The relationship of the ubiquitin proteasome system and the regulation of apoptosis has been generally established in non-muscle and muscle cell types [52–54]. However, the inhibition of proteasome has been shown to have opposite effects in inducing and suppressing apoptosis in multiple cell types [52–54]. It has been postulated that the opposite effects of proteasome inhibition might be partly attributed to the differentiation status of the cell types [52–54]. Although the precise association of proteasome and apoptosis remains to be elucidated, our findings indicated that compression-induced muscle pathohistology accompanied by increased DNA fragmentation could be alleviated by the administration of the proteasome inhibitor MG132. Whether the observed inhibitory effect of MG132 on the compression-induced elevation of TUNEL-determined DNA fragmentation might be related to the highly differentiated postmitotic nature of skeletal muscle remains to be elucidated.

With reference to the results reported by Kwan and co-workers [29], the present study reproduced the pathologic histology in muscle tissue by adopting a similar compression protocol. It is noted that the observed pathologic characteristics were located in the zone underneath the indenter and ranged from indenter to bone as indicated by our histological analysis. It has been suggested that the tolerance and resistance to mechanical compression in muscle tissue is lower than that in soft tissues, such as cutaneous tissue [23–26]. In agreement with the suggestion that muscle tissue is more susceptible to pressure-related injury, our data showed that the pathologic characteristics were exclusively observed in the underlying muscle tissue whereas no apparent histological indication of injury was found in the skin layer (data not shown). It is noted that the present observations are consistent with the previous findings in the etiology of deep tissue injury using an animal model with controlled external loading techniques [55, 56]. Those findings showed that damage was incident to the soft tissues in the zone underneath the indenter and consisted of loss of cross-striation and infiltration of macrophages [55, 56]. It appears that muscle tissues directly enveloping bone surfaces are more vulnerable to pressure and resulting in pathologic change probably because of the high concentrated load and mechanical stress that the muscle needs to bear with compression. Accompanied by the demonstrated pathologic role of the ubiquitin proteasome system, the present study put forward muscle as an important initiating site for deep pressure ulcer. These findings warrant further investigation in comprehensively identifying the precise etiologic role of muscle in pressure-induced deep tissue injury.

Conclusion

Our results demonstrated the elevation of ubiquitin, MAFbx/atrogin-1, and 20S proteasome activity in the presence of pathohistology in muscle following sustained compression in an experimental deep pressure ulcer rat model. The administration of the proteasome inhibitor MG132 was effective in preventing the pathohistology, increase in ubiquitin and MAFbx/atrogin-1, and increase in 20S proteasome activity caused by compression. Our results are consistent with the hypothesis that the muscle ubiquitin proteasome system is involved in the pathology of pressure-induced deep tissue injury. These findings suggest that the ubiquitin proteasome system could be a potential molecular target for exploring therapeutic interventions to treat pressure-induced deep tissue injury.

Declarations

Acknowledgements

This study was supported by The Hong Kong Polytechnic University ICRG Research Funds A-PH69, A-PA7N and G-U645. The authors acknowledged the technical help of Joann Ng. The authors gratefully acknowledged the critical reading of Prof. Iris Benzie and S.W. Choi.

Authors’ Affiliations

(1)
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China

References

  1. Garcia AD, Thomas DR: Assessment and management of chronic pressure ulcers in the elderly. Med Clin North Am. 2006, 90: 925-944. 10.1016/j.mcna.2006.05.018.View ArticlePubMedGoogle Scholar
  2. Cullum N, McInnes E, Bell-Syer SE, Legood R: Support surfaces for pressure ulcer prevention. Cochrane Database Syst Rev. 2004, CD001735-Google Scholar
  3. Gawlitta D, Li W, Oomens CW, Baaijens FP, Bader DL, Bouten CV: The relative contributions of compression and hypoxia to development of muscle tissue damage: an in vitro study. Ann Biomed Eng. 2007, 35: 273-284. 10.1007/s10439-006-9222-5.View ArticlePubMedGoogle Scholar
  4. Ankrom MA, Bennett RG, Sprigle S, Langemo D, Black JM, Berlowitz DR, Lyder CH: Pressure-related deep tissue injury under intact skin and the current pressure ulcer staging systems. Adv Skin Wound Care. 2005, 18: 35-42. 10.1097/00129334-200501000-00016.View ArticlePubMedGoogle Scholar
  5. Black J, Baharestani M, Cuddigan J, Dorner B, Edsberg L, Langemo D, Posthauer ME, Ratliff C, Taler G: National Pressure Ulcer Advisory Panel's updated pressure ulcer staging system. Urol Nurs. 2007, 27: 144-50. 156PubMedGoogle Scholar
  6. Donnelly J: Should we include deep tissue injury in pressure ulcer staging systems? The NPUAP debate. J Wound Care. 2005, 14: 207-210.View ArticlePubMedGoogle Scholar
  7. Gefen A: Bioengineering models of deep tissue injury. Adv Skin Wound Care. 2008, 21: 30-36. 10.1097/01.ASW.0000305403.89737.6c.View ArticlePubMedGoogle Scholar
  8. Fleck CA: Suspected deep tissue injury. Adv Skin Wound Care. 2007, 20: 413-415. 10.1097/01.ASW.0000280206.96378.5b.View ArticlePubMedGoogle Scholar
  9. Gefen A: Risk factors for a pressure-related deep tissue injury: a theoretical model. Med Biol Eng Comput. 2007, 45: 563-573. 10.1007/s11517-007-0187-9.View ArticlePubMedGoogle Scholar
  10. Arnason T, Ellison MJ: Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain. Mol Cell Biol. 1994, 14: 7876-7883.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ: Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000, 103: 351-361. 10.1016/S0092-8674(00)00126-4.View ArticlePubMedGoogle Scholar
  12. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004, 430: 694-699. 10.1038/nature02794.View ArticlePubMedGoogle Scholar
  13. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002, 82: 373-428.View ArticlePubMedGoogle Scholar
  14. Taillandier D, Combaret L, Pouch MN, Samuels SE, Bechet D, Attaix D: The role of ubiquitin-proteasome-dependent proteolysis in the remodelling of skeletal muscle. Proc Nutr Soc. 2004, 63: 357-361. 10.1079/PAR2004358.View ArticlePubMedGoogle Scholar
  15. Zhang P, Chen X, Fan M: Signaling mechanisms involved in disuse muscle atrophy. Med Hypotheses. 2007, 69: 310-321. 10.1016/j.mehy.2006.11.043.View ArticlePubMedGoogle Scholar
  16. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001, 294: 1704-1708. 10.1126/science.1065874.View ArticlePubMedGoogle Scholar
  17. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 2001, 98: 14440-14445. 10.1073/pnas.251541198.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Franch HA, Price SR: Molecular signaling pathways regulating muscle proteolysis during atrophy. Curr Opin Clin Nutr Metab Care. 2005, 8: 271-275. 10.1097/01.mco.0000165005.01331.45.View ArticlePubMedGoogle Scholar
  19. Miyazaki M, Noguchi M, Takemasa T: Intermittent reloading attenuates muscle atrophy through modulating Akt/mTOR pathway. Med Sci Sports Exerc. 2008, 40: 848-855. 10.1249/MSS.0b013e318163275f.View ArticlePubMedGoogle Scholar
  20. de Palma L, Marinelli M, Pavan M, Orazi A: Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine. 2008, 75: 53-57. 10.1016/j.jbspin.2007.04.019.View ArticlePubMedGoogle Scholar
  21. Edlich RF, Winters KL, Woodard CR, Buschbacher RM, Long WB, Gebhart JH, Ma EK: Pressure ulcer prevention. J Long Term Eff Med Implants. 2004, 14: 285-304. 10.1615/JLongTermEffMedImplants.v14.i4.20.View ArticlePubMedGoogle Scholar
  22. Struck BD, Wright JE: Pressure ulcers and endothelial dysfunction: is there a link?. J Nutr Elder. 2007, 26: 105-117. 10.1300/J052v26n03_05.View ArticlePubMedGoogle Scholar
  23. Bouten CV, Oomens CW, Baaijens FP, Bader DL: The etiology of pressure ulcers: skin deep or muscle bound?. Arch Phys Med Rehabil. 2003, 84: 616-619. 10.1053/apmr.2003.50038.View ArticlePubMedGoogle Scholar
  24. Daniel RK, Priest DL, Wheatley DC: Etiologic factors in pressure sores: an experimental model. Arch Phys Med Rehabil. 1981, 62: 492-498.PubMedGoogle Scholar
  25. Nola GT, Vistnes LM: Differential response of skin and muscle in the experimental production of pressure sores. Plast Reconstr Surg. 1980, 66: 728-733. 10.1097/00006534-198011000-00008.View ArticlePubMedGoogle Scholar
  26. Salcido R, Donofrio JC, Fisher SB, LeGrand EK, Dickey K, Carney JM, Schosser R, Liang R: Histopathology of pressure ulcers as a result of sequential computer-controlled pressure sessions in a fuzzy rat model. Adv Wound Care. 1994, 7: 23-4. 26, 28PubMedGoogle Scholar
  27. Attaix D, Ventadour S, Codran A, Bechet D, Taillandier D, Combaret L: The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 2005, 41: 173-186. 10.1042/EB0410173.View ArticlePubMedGoogle Scholar
  28. Cao PR, Kim HJ, Lecker SH: Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol. 2005, 37: 2088-2097. 10.1016/j.biocel.2004.11.010.View ArticlePubMedGoogle Scholar
  29. Kwan MP, Tam EW, Lo SC, Leung MC, Lau RY: The time effect of pressure on tissue viability: investigation using an experimental rat model. Exp Biol Med (Maywood). 2007, 232: 481-487.Google Scholar
  30. Siu PM, Tam EW, Teng BT, Pei XM, Ng JW, Benzie IF, Mak AF: Muscle apoptosis is induced in pressure-induced deep tissue injury. J Appl Physiol. 2009, 107: 1266-1275. 10.1152/japplphysiol.90897.2008.View ArticlePubMedGoogle Scholar
  31. Teng BT, Pei XM, Tam EW, Benzie IF, Siu PM: Opposing responses of apoptosis and autophagy to moderate compression in skeletal muscle. Acta Physiol (Oxf). 2010, 201: 239-254. 10.1111/j.1748-1716.2010.02173.x.View ArticleGoogle Scholar
  32. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994, 78: 761-771. 10.1016/S0092-8674(94)90462-6.View ArticlePubMedGoogle Scholar
  33. Chen X, Li SL, Wu T, Liu JD: Proteasome inhibitor ameliorates severe acute pancreatitis and associated lung injury of rats. World J Gastroenterol. 2008, 14: 3249-3253. 10.3748/wjg.14.3249.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Yuan B, Xing Y, Horst RL, Drezner MK: Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in the hyp-mouse. Endocrinology. 2004, 145: 3804-3812. 10.1210/en.2004-0192.View ArticlePubMedGoogle Scholar
  35. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
  36. Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996, 335: 1897-1905. 10.1056/NEJM199612193352507.View ArticlePubMedGoogle Scholar
  37. Granado M, Martin AI, Priego T, Lopez-Calderon A, Villanua MA: Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J Endocrinol. 2006, 191: 319-326. 10.1677/joe.1.06931.View ArticlePubMedGoogle Scholar
  38. Nedergaard A, Vissing K, Overgaard K, Kjaer M, Schjerling P: Expression patterns of atrogenic and ubiquitin proteasome component genes with exercise: effect of different loading patterns and repeated exercise bouts. J Appl Physiol. 2007, 103: 1513-1522. 10.1152/japplphysiol.01445.2006.View ArticlePubMedGoogle Scholar
  39. Witt CC, Witt SH, Lerche S, Labeit D, Back W, Labeit S: Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 2008, 27: 350-360. 10.1038/sj.emboj.7601952.View ArticlePubMedGoogle Scholar
  40. Drummond MJ, Glynn EL, Lujan HL, Dicarlo SE, Rasmussen BB: Gene and protein expression associated with protein synthesis and breakdown in paraplegic skeletal muscle. Muscle Nerve. 2008, 37: 505-513. 10.1002/mus.20976.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Koyama S, Hata S, Witt CC, Ono Y, Lerche S, Ojima K, Chiba T, Doi N, Kitamura F, Tanaka K, Abe K, Witt SH, Rybin V, Gasch A, Franz T, Labeit S, Sorimachi H: Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J Mol Biol. 2008, 376: 1224-1236. 10.1016/j.jmb.2007.11.049.View ArticlePubMedGoogle Scholar
  42. Lang CH, Huber D, Frost RA: Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol. 2007, 292: R328-R336.View ArticlePubMedGoogle Scholar
  43. Vary TC, Frost RA, Lang CH: Acute alcohol intoxication increases atrogin-1 and MuRF1 mRNA without increasing proteolysis in skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2008, 294: R1777-R1789.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Dehoux MJ, van Beneden RP, Fernandez-Celemin L, Lause PL, Thissen JP: Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett. 2003, 544: 214-217. 10.1016/S0014-5793(03)00505-2.View ArticlePubMedGoogle Scholar
  45. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP: Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol. 2003, 163: 1663-1675. 10.1016/S0002-9440(10)63523-7.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Assereto S, Stringara S, Sotgia F, Bonuccelli G, Broccolini A, Pedemonte M, Traverso M, Biancheri R, Zara F, Bruno C, Lisanti MP, Minetti C: Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. Am J Physiol Cell Physiol. 2006, 290: C577-C582. 10.1152/ajpcell.00434.2005.View ArticlePubMedGoogle Scholar
  47. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J: A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation. 2001, 72: 196-202. 10.1097/00007890-200107270-00005.View ArticlePubMedGoogle Scholar
  48. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA. 1999, 96: 10403-10408. 10.1073/pnas.96.18.10403.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Petrovic J, Hall H, Mehr R, Glas R, Hoglund P: Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice. Scand J Immunol. 2004, 60: 134-142. 10.1111/j.0300-9475.2004.01473.x.View ArticlePubMedGoogle Scholar
  50. Wang X, Luo H, Chen H, Duguid W, Wu J: Role of proteasomes in T cell activation and proliferation. J Immunol. 1998, 160: 788-801.PubMedGoogle Scholar
  51. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH: Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest. 2002, 109: 671-679.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Wojcik C: Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med. 2002, 6: 25-48. 10.1111/j.1582-4934.2002.tb00309.x.View ArticlePubMedGoogle Scholar
  53. Drexler HC: Programmed cell death and the proteasome. Apoptosis. 1998, 3: 1-7. 10.1023/A:1009604900979.View ArticlePubMedGoogle Scholar
  54. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999, 6: 303-313. 10.1038/sj.cdd.4400505.View ArticlePubMedGoogle Scholar
  55. Bosboom EM, Bouten CV, Oomens CW, van Straaten HW, Baaijens FP, Kuipers H: Quantification and localisation of damage in rat muscles after controlled loading; a new approach to study the aetiology of pressure sores. Med Eng Phys. 2001, 23: 195-200. 10.1016/S1350-4533(01)00034-0.View ArticlePubMedGoogle Scholar
  56. Stekelenburg A, Oomens CW, Strijkers GJ, Nicolay K, Bader DL: Compression-induced deep tissue injury examined with magnetic resonance imaging and histology. J Appl Physiol. 2006, 100: 1946-1954. 10.1152/japplphysiol.00889.2005.View ArticlePubMedGoogle Scholar

    57. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/12/58/prepub

Copyright

© Siu et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us